Download Bronchial carcinoma

Tumors of the bronchus and lung
Risk Factors:
 Cigarette smoking is by far the most important cause of lung cancer. for at least 90 being
proportional to the amount smoked and to the tar content of cigarettes.
The death rate from the disease in heavy smokers is 40 times that in non-smokers. Risk falls
slowly after smoking cessation, but remains above that in non-smokers for many years
 Exposure to naturally occurring radon is another risk.
 The incidence of lung cancer is slightly higher in urban than in rural dwellers which may reflect
differences in atmospheric.
Bronchial carcinoma
The incidence of bronchial carcinoma increased dramatically during the 20th century as a direct
result of the tobacco epidemic.
In women, smoking prevalence and deaths from lung cancer continue to increase, and more
women now die of lung cancer than breast cancer in the USA and the UK
Bronchial carcinomas arise from the bronchial epithelium or mucous glands.
The common cell types are:
 Squamous 35%,
 Adenocarcinoma 30%,
 Small-cell 20%,
 Large-cell 15%.
Tumour occurs in a large bronchus, symptoms arise early, but tumours originating in a peripheral
bronchus can grow very large without producing symptoms, resulting in delayed diagnosis.
Peripheral squamous tumours may undergo central necrosis and cavitation, and may resemble a
lung abscess on X-ray .
Spread
Bronchial carcinoma may involve the pleura either directly or by lymphatic spread and may
extend into the chest wall, invading the intercostal nerves or the brachial plexus and causing pain.
Lymphatic spread to mediastinal and supraclavicular lymph nodes frequently occurs prior to
diagnosis.
Blood-borne metastases occur most commonly in liver, bone, brain, adrenals and skin. Even a
small primary tumour may cause widespread metastatic deposits and this is a particular
characteristic of small-cell lung cancers.
Clinical Presentation of Bronchial carcinoma
1
 Cough: The most common early symptom, cough is often dry; however, secondary infection may
cause purulent sputum. A change in the character of a smoker's cough, particularly if associated
with other new symptoms, should always raise suspicion of bronchial carcinoma.
 Haemoptysis: This is common, especially with central bronchial tumours. Although it may be
benign, haemoptysis in a smoker should always be investigated to exclude a bronchial carcinoma.
 Occasionally, central tumours invade large vessels, causing sudden massive haemoptysis which
may be fatal
 Bronchial obstruction: The clinical and radiological manifestations depend on the site and extent
of the obstruction, any secondary infection, and the extent of coexisting lung disease.
 Complete obstruction: causes collapse of a lobe or lung, with breathlessness, mediastinal
displacement and dullness to percussion with reduced breath sounds.
 Partial bronchial obstruction: may cause a monophonic, unilateral wheeze that fails to clear
with coughing and may also impair the drainage of secretions sufficiently to cause pneumonia or
lung abscess as a presenting problem.
 Pneumonia: that recurs at the same site or responds slowly to treatment, particularly in a smoker,
should always suggest an underlying bronchial carcinoma.
 Stridor: (a harsh inspiratory noise) occurs when the lower trachea, carina or main bronchi are
narrowed by the primary tumour or by compression from malignant enlargement of the subcarinal
and paratracheal lymph nodes.
 Breathlessness: This may be caused by collapse or pneumonia, or by tumour causing a large
pleural effusion or compressing a phrenic nerve causing diaphragmatic paralysis.
 Pain and nerve entrapment: Pleural pain usually indicates malignant pleural invasion, although
it can occur with distal infection. Intercostal nerve involvement causes pain in the distribution of a
thoracic dermatome.
 Carcinoma in the lung apex: may cause Horner's syndrome (ipsilateral partial ptosis,
enophthalmos, miosis and hypohidrosis of the face due to involvement of the sympathetic chain at
or above the stellate ganglion.
 Pancoast's syndrome: pain in the shoulder and inner aspect of the arm, sometimes with small
muscle wasting in the hand indicates malignant destruction of the T1 and C8 roots in lower part of
the brachial plexus by an apical lung tumour.
 Mediastinal spread: Involvement of the oesophagus may cause dysphagia.
 If the pericardium is invaded, arrhythmia or pericardial effusion may occur.
 Superior vena cava obstruction by malignant nodes causes suffusion and swelling of the neck
and face, conjunctival oedema, headache and dilated veins on the chest wall, and is most
commonly due to bronchial carcinoma.
 Involvement of the left recurrent laryngeal nerve by tumours at the left hilum causes vocal cord
paralysis, voice alteration and a 'bovine' cough (lacking the normal explosive character).
 Supraclavicular lymph nodes may be palpably enlarged; if so, a needle aspirate may provide a
simple means of cytological diagnosis.
 Metastatic spread: This may lead to focal neurological defects, epileptic seizures, personality
change, jaundice, bone pain or skin nodules. Lassitude, anorexia and weight loss usually indicate
metastatic spread.
2
 Digital clubbing. Overgrowth of the soft tissue of the terminal phalanx leading to increased nail
curvature is often seen.
 This may be associated with hypertrophic pulmonary osteoarthropathy (HPOA), characterised
by periostitis of the long bones, most commonly the distal tibia, fibula, radius and ulna.
 This causes pain and tenderness over the affected bones and often pitting oedema over the anterior
aspect of the shin. X-rays reveal subperiosteal new bone formation. While most frequently
associated with bronchial carcinoma, HPOA can occur with other tumours.
 Non-metastatic extrapulmonary effects .Syndrome of inappropriate antidiuretic hormone
secretion (SIADH) and ectopic adrenocorticotrophic hormone secretion are usually associated
with small-cell lung cancer
 Hypercalcaemia is usually caused by squamous cell carcinoma.
 Associated neurological syndromes may occur with any type of bronchial carcinoma
 Non-metastatic extrapulmonary manifestations of bronchial carcinoma
Endocrine
 Inappropriate antidiuretic hormone secretion causing hyponatraemia
 Ectopic adrenocorticotrophic hormone secretion
 Hypercalcaemia due to secretion of parathyroid hormone-related peptides
 Carcinoid syndrome
 Gynaecomastia
Neurological
 Polyneuropathy
 Myelopathy
 Cerebellar degeneration
 Myasthenia (Lambert-Eaton syndrome).
Other
 Digital clubbing
 Hypertrophic pulmonary osteoarthropathy
 Nephrotic syndrome
 Polymyositis and dermatomyositis
 Eosinophilia
Investigations for Bronchial carcinoma
 Plain X-rays
 CT is usually performed for :
 localization,operability, metastatic spread
 and for accessible or not by bronchoscopy .
 Bronchoscopy: three-quarters of primary lung tumours can be visualised and sampled directly by
biopsy and brushing using a flexible bronchoscope.
3
 Percutaneous needle biopsy under CT or ultrasound guidance; more reliable way to obtain a
histological diagnosis for tumours which are too peripheral








Common radiological presentations of bronchial carcinoma
Unilateral hilar enlargement
Peripheral pulmonary opacity
Lung, lobe or segmental collapse
Pleural effusion
Broadening of mediastinum
Enlarged cardiac shadow
Elevation of a hemidiaphragm
Rib destruction
Staging to guide treatment
• The propensity of small-cell lung cancer to metastasise early dictates that patients with this
tumour type are usually not suitable for surgical intervention.
• In patients with other cell types, subsequent investigations should focus on determining whether
the tumour is operable, because complete resection may be curative.
• While CT may show obvious spread of disease, for many patients the results are equivocal and
further investigation is required before deciding whether curative surgery is feasible.
• Enlarged upper mediastinal nodes may be sampled by using a bronchoscope equipped with
endobronchial ultrasound (EBUS) or by mediastinoscopy.
• Nodes in the lower mediastinum can be sampled through the oesophageal wall using endoscopic
ultrasound.
• Combined CT and PET imaging is used increasingly to detect metabolically active tumour
metastases.
• Head CT, radionuclide bone scanning, liver ultrasound and bone marrow biopsy are generally
reserved for patients with clinical, haematological or biochemical evidence of tumour spread to
such sites.
• Finally, detailed physiological testing is required to ensure that the patient's respiratory and
cardiac function is sufficient to allow surgical treatment.
Contraindications to surgical resection in bronchial carcinoma
•
•
•
•
•
•
Distant metastasis (M1)
Invasion of central mediastinal structures including heart, great vessels, trachea and
oesophagus (T4)
Malignant pleural effusion (T4)
Contralateral mediastinal nodes (N3)
FEV1 < 0.8 L
Severe or unstable cardiac or other medical condition
4
Management
•
•
•
Surgical resection carries the best hope of long-term survival; however, some patients
treated with radical radiotherapy and chemotherapy also achieve prolonged remission or
cure.
Unfortunately, in over 75% of cases, treatment with curative intent is not possible, or is
inappropriate due to extensive spread or comorbidity. Such patients can only be offered
palliative therapy and best supportive care.
Radiotherapy, and in some cases chemotherapy, can relieve distressing symptoms.
Treatment and Staging NSCLC
Surgical treatment: Accurate pre-operative staging, coupled with improvements in surgical and
post-operative care, now offers 5-year survival rates of over 75% in stage I disease (N0, tumour
confined within visceral pleura) and 55% in stage II disease, which includes resection in patients
with ipsilateral peribronchial or hilar node involvement.
Radiotherapy : While much less effective than surgery, radical radiotherapy can offer long-term
survival in selected patients with localised disease in whom comorbidity precludes surgery.
The greatest value of radiotherapy, however, is in the palliation of distressing complications such
as superior vena cava obstruction, recurrent haemoptysis, and pain caused by chest wall invasion
or by skeletal metastatic deposits.
Obstruction of the trachea and main bronchi can also be relieved temporarily.
Radiotherapy can be used in conjunction with chemotherapy in the treatment of small-cell
carcinoma, and is particularly efficient at preventing the development of brain metastases in
patients who have had a complete response to chemotherapy.
Chemotherapy: The treatment of small-cell carcinoma with combinations of cytotoxic drugs,
sometimes in combination with radiotherapy, can increase the median survival from 3 months to
well over a year.
5
Combination chemotherapy leads to better outcomes than single-agent treatment.
In general, chemotherapy is less effective in non-small-cell bronchial cancers. However, studies in
such patients using platinum-based chemotherapy regimens have shown a 30% response rate
associated with a small increase in survival.
Neoadjuvant and adjuvant chemotherapy : In non-small-cell carcinoma, there is some evidence
that chemotherapy given before surgery may increase survival and can effectively 'down-stage'
disease with limited nodal spread.
Post-operative chemotherapy is now proven to improve survival rates when operative samples
show nodal involvement by tumour.
Laser therapy and stenting : Palliation of symptoms caused by major airway obstruction can be
achieved in selected patients using bronchoscopic laser treatment to clear tumour tissue and allow
re-aeration of collapsed lung.
The best results are achieved in tumours of the main bronchi. Endobronchial stents can be used to
maintain airway patency in the face of extrinsic compression by malignant nodes.
Prognosis : The overall prognosis in bronchial carcinoma is very poor, with around 70% of
patients dying within a year of diagnosis and only 6-8% of patients surviving 5 years after diagnosis.
The best prognosis is with well-differentiated squamous cell tumours that have not metastasised and
are amenable to surgical resection.
Secondary tumours of the lung
•
•
•
•
•
Blood-borne metastatic deposits in the lungs may be derived from many primary tumours,
in particular those of the breast, kidney, uterus, ovary, testes and thyroid.
The secondary deposits are usually multiple and bilateral.
Often there are no respiratory symptoms and the diagnosis is made on radiological
examination.
Breathlessness may occur if a considerable amount of lung tissue has been replaced by
metastatic tumour.
Endobronchial deposits are uncommon but can cause haemoptysis and lobar collapse.
6